http://www.ventrusbio.com/content/index.html http://investor.ventrusbio.com/
http://finance.yahoo.com/q/ks?s=VTUS+Key+Statistics Ventrus Biosciences, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders primarily hemorrhoids, anal fissures, and fecal incontinence. It is developing three late-stage product candidates, which include Iferanserin ointment (VEN 309) for the topical treatment of hemorrhoids; Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis or IPAA, an FDA orphan indication. The company was formerly known as South Island Biosciences, Inc. and changed its name to Ventrus Biosciences, Inc. in April 2007. Ventrus Biosciences was founded in 2005 and is based in New York, New York.
